Pekin Hardy Strauss’s CorMedix CRMD Stock Holding History

Pekin Hardy Strauss’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$424K	Buy	54,000 +36,000	+200%	+$284K	0.04%	340
2026 Q1	$122K	Sell	18,000 -1,000	-5%	-$7.39K	0.01%	458
2025 Q4	$221K	Buy	+19,000	New	+$210K	0.02%	402

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pekin Hardy Strauss's CRMD Position: Q2 2026 in Review

Pekin Hardy Strauss increased its CorMedix (CRMD) stake by 200% in Q2 2026, buying an estimated $284K and bringing the position to 54,000 shares worth $424K. The position accounts for 0.04% of the portfolio, ranked #340.

Pekin Hardy Strauss first reported a position in CRMD in Q4 2025 and has held it in 3 quarters since. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Pekin Hardy Strauss held 54,000 shares of CorMedix worth $424K as of Q2 2026.
Pekin Hardy Strauss bought 36,000 CorMedix shares in Q2 2026, an estimated $284K.
CorMedix made up 0.04% of Pekin Hardy Strauss's portfolio in Q2 2026, its #340 holding.
Pekin Hardy Strauss first reported a position in CorMedix in Q4 2025 and has held it in 3 quarters since.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.